|
Doug Watson has been a director since BioMimetic's inception. Mr. Watson's career spanned 33 years with Geigy/Ciba-Geigy/Novartis, in a variety of positions in the UK, Switzerland and the US. From 1986 to 1996, he was President of Ciba Pharmaceuticals Division and was appointed President and Chief Executive Officer of Ciba-Geigy Corporation in 1996. Mr. Watson became President and Chief Executive Officer of Novartis Corporation in 1997 when the merger of Ciba-Geigy and Sandoz was approved by the FTC. In May 1999, Mr. Watson elected to take early retirement from Novartis. That same year he founded Pittencrieff Glen Associates, a private management consulting company. In addition to BioMimetic, he has served as the chairman of OraSure Technologies Inc. since March 2003 and as a director since April 2002. He has served as the chairman of Innovative Drug Delivery Systems Inc. since June 2003 and as a director since March 2001. He currently serves as a director on the boards of Engelhard Corporation since 1991, Dendreon Corporation since March 2000, Genta Inc. since April 2002, BioElectronics Inc. since November 2002 and InforMedix Inc. since March 2002. From July 2000 to September 2001, he also served as a member of the Board and acting Chief Executive Officer of ValiGen N.V. He is also a member of the President's Advisory Board of Drew University. Mr. Watson holds an M.A. degree in pure mathematics from Churchill College, Cambridge University, and is a member of the Chartered Institute of Management Accountants. | 